27 February 2019 - - Switzerland-based Selexis SA and Turkey-based Turgut Pharmaceuticals (Turgut Ilaclari A.S.)  have signed two commercial license agreements through which Turgut will leverage Selexis' SUREtechnologyPlatform and SURE CHO-M Cell Line for the development of two biosimilar antibodies: a checkpoint inhibitor for the treatment of certain cancers and a monoclonal antibody for the treatment of metastatic HER2-positive breast cancer, the companies said.

With the addition of these CLAs, the companies are now working together to develop multiple biosimilar products in cancer and inflammatory diseases.

The companies announced the signing of the most recent previous CLAs in December 2017.

Selexis' proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including biosimilars, and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

Utilising the SUREtechnology Platform, Selexis has successfully generated numerous biosimilars, including marketed products, that have glycan profiles matching originator products.

The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies.

The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors.

Therapeutics that are generated using Selexis SURE CHO-M cells are in both clinical trials and marketed products.

Selexis in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialise innovative medicines and vaccines.

Its global partners are utilising Selexis technologies to advance more than 110 drug products in clinical development and the manufacture of four commercial products.

In June 2017, Selexis became part of the JSR Life Sciences group. JSR's CDMO service offering leverages the full capabilities of Selexis' proprietary SUREtechnology Platform to offer an end-to-end solution to industry.

Turgut Group, with over 50 years' experience, has recently incorporated its pharmaceutical activities under the roof of Turgut Pharmaceuticals, with a focus on biotechnology.

With its global collaborations, a fully integrated monoclonal antibody development platform and global standard GMP biotechnology manufacturing facility, Turgut Pharmaceuticals is a leading biotech company in Turkey with the vision to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States.